Under the terms of the new agreement, AstraZeneca and Moderna, a pioneer of mRNA Therapeutics ™, have agreed to collaborate on two
specific immuno - oncology programs, based on promising pre-clinical data, including pharmacology in tumor models.
Not exact matches
Our
immuno - oncology product candidates are being developed in two separate approaches: one that targets
specific antigens and / or epitopes (such as CMB305 and in our neoantigen collaboration); and an alternative approach that leverages the endogenous antigens found in the tumor microenvironment via intratumoral immunization (such as G100).
Our
immuno - oncology product candidates use two different strategies referred to as the
Specific Antigen and Intratumoral immune activation / Endogenous Antigen approaches.